Advances in inmunnology of transplants

Authors

  • Franklin Torres Jiménez Universidad Libre

DOI:

https://doi.org/10.18041/2390-0512/bioc..1.2765

Keywords:

Transplant, Major histocompatibility complex, Rejection, Tolerance

Abstract

Transplantation is the process of grafting cells or tissues from one person (donor) to another (recipient), in or- der to replace tissues or organs that have lost their biological function. One of the drawbacks in the success of this practice is the immune rejection of the organ transplanted, due to genetic and phenotypic differences that exist between the donor and the recipient (molecules of the major histocompatibility complex, complex minor histocompatibility antigens in the system and ABO). There are medications that have the function of preventing the rejection of grafts. However, prolonged use of these creates immunosuppression nonspecific, predispose to the development of infection by opportunistic microbes and neoplasms. New advances in transplant medicine have allowed the development of more specific drugs, and even new strategies to induce tolerance in trasplant patients. Under this perspective, this bibliographic review was developed, with the objective of providing new knowledge related to Immunology of transplants.

Downloads

Download data is not yet available.

References

Martínez-Álvarez JC. El papel del complejo principal de histocompatibilidad en el trasplan- te de células progenitoras hematopoyéticas. Revista Médica del IMSS. 2005; 43(Supl 1):87- 9.

Arizón del Prado JM. Pautas inmunosupreso- ras. Diferencias y ventajas. Rev Esp Cardiol. 1995; 48(Supl 7):71-6.

Barrios C, Garrido A, Pereira F, Jiménez M, Ar- dáiz J. Fármacos inmunosupresores. Curso de actualización en trasplante hepático. Madrid: Ed. Drug Farma. 1998:161-76.

Eugui EM. Presente y futuro de la terapia in- munosupresora. Medicina (Buenos Aires). 2000; 60(1):67-80.

Cuervas-Mons V, del Castillo-Olivares JL. Intro- ducción al trasplante de órganos y tejidos. Ma- drid: Ed. Arán. 1999: 173-94.

Sayegh MH, Carpenter CB. Transplantation 50 years later: progress, challenges, and promi- ses. N Eng J Med. 2004; 351:2761-6.

Moreno D, Mármol A y Pérez de Prado JC. Com- patibilidades HLA anticuerpos linfocitotóxicos y rechazo en el trasplante renal. Nefrología. 1999; XIX (6):567-8.

Beck S. Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature. 1999; 401:921-5.

Marsh SGE, Ekkehard DA, Walter A, Bodmer F, Bontrop RE, Dupont B, Erlich HA, et al. Nomen- clature for factors of the HLA system, 2002. Tis- sue Antigens. 2002; 60:407-64.

Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, et al. Banff’05 meeting report: di- fferential diagnosis of chronic allograft injury and elimination of chronic allograft nephro- pathy (‘CAN’). Am J Transplant. 2007; 7:518- 26.

Gómez-Morales E. Importancia del fenotipo eritrocitario en el trasplante de células hema- topoyéticas. Gac Méd Méx. 2004; 140:(Supl)3.

Wagrowska-Danilewicz M and Danilewicz M. Immunoexpression of perforin and granzyme B on infiltrating lymphocytes in human renal acute allograft rejection. Nefrología. 2003; 23(6):538-44.

Milford EL, Hancock W, Carpenter Ch B. Immu- nopathogenetic mechanisms of allograft re- jection in Renal Pathology vol II. Philadelphia: Craig Tisher. B Brenner edit. J.B. Lippincott Co. 1994: 1581-90.

Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM et al. Antibody-me- diated rejection criteria - an addition to the Banff’97 Classification of Renal Allograft Rejec- tion. Am J Transplant. 2003; 3(6):708-14.

Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M et al. Banff’07 Classification of Renal Allograft Pathology: Updates and Future Direc- tions. Am J Transplant. 2008; 8(4):753-60.

Cuervas-Mons V. Medicamentos inmunosu- presores II. Azatioprina. Micofenolato, Mofetil, Mizoribina, Brequinar sódico, Deoxisperguali- na, Anticuerpos policlonales antilinfocitarios, Anticuerpos monoclonales OKT3, Otros anti- cuerpos monoclonales, Esteroides. En: Cuer- vas-Mons V, del Castillo-Olivares JL. Introduc- ción al trasplante de órganos y tejidos. Madrid: Ed. Arán. 1999: 173-94.

Cuervas-Mons V. Medicamentos inmunosu- presores I. Ciclosporina. Tacrolimus. Sirolimus. En: Cuervas-Mons V, Del Castillo-Olivares JL. Introducción al trasplante de órganos y tejidos. Madrid: Ed. Arán. 1999: 145-72.

Gómez R, González-Pinto I, Loinaz C, García I, Abradelo M, Rodríguez A, et al. Inmunosupre- sión actual en el trasplante de órganos abdo- minales. En: Moreno González E, Gómez Sanz R. Presente y futuro del trasplante de órganos abdominales. Madrid: Ed. Novartis. 1997: 53- 66.

Dupont E, Wybran J, Toussaint C. Glucocorti- costeroids and organ transplantation. Trans- plantation, 1984. 37:331-5.

Shapiro R, Jordan ML, Scantlebury VP. Ran- domized Trial of FK506/prednisone vs FK506/ azathioprine/prednisone after renal transplan- tation: preliminary report. Transplant. Proc. 1993; 25:669-72.

Wilde MI, Goa KL. Muromonab CD3 a reapprai- sal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs. 1996; 51:865-94.

Kim YM, et al. Ex vivo expansion of human um- bilical cord blood-derived T-lymphocytes with homologous cord blood plasma. Tohoku J Exp Med. 2005; 205(2):115-22.

Maes BD, Vanrenterghem YF. Anti-interleukin-2 receptor monoclonal antibodies in renal trans- plantation. Nephrol Dial. Transplant. 1999; 14: 2824-6.

Legendre C, Kreis H, Bach JF, Chatenoud L. Prediction of successful allograft rejection re- treatment with OKT3. Transplantation. 1992; 53:87-90.

Kovarik J, Wolf P, Cisterne JM, Mourad G, Le- branchu Y, Lang P, et al. Disposition of basilixi- mab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cada- verrenal allografts. Transplantation. 1997; 64: 1701-5.

Waid Thomas H, Thompson John S, Siemionow Maria, and Brown Stephen A. T10B9 monoclo- nal antibody: A short-acting nonstimulating monoclonal antibody that spares γδ T-cells and treats and prevents cellular rejection. Drug Des Devel Ther. 2009; 3:205-12.

Reinherz Ellis L, Kung Patrick C, Goldstein Gi- deon and Schlossman Further Stuart F. Charac- terization of the Human Inducer T Cell Subset Defined by Monoclonal Antibody. The Journal of Immunology. 1979; 123:2894-6.

Carretero M. Daclizumab es un anticuerpo mo- noclonal IgG1 humanizado, obtenido mediante ingeniería genética que se une a la subunidad Tac del receptor de interleucina-2, expresado en los linfocitos T humanos activados. Está in- dicado en la prevención del rechazo agudo en Biociencias • Volumen 6 • Número 1 • 81 - 88 • Enero-Junio 2011 • Universidad Libre Seccional Barranquilla pacientes receptores de trasplantes renales alogénicos. OFFARM 2002; 21(3):132-5.

Starzl TE. Chimerism and tolerance in trans- plantation. Proc Natl Acad Sci USA 101. 2004; (Suppl 2):1460. 7-14.

Starzl TE, Zinkernagel RM. Antigen localization and migration in immunity and tolerance. N Engl J Med. 1998; 339:1905-13.

Downloads

Published

2011-06-01

Issue

Vol. 6 No. 1 (2011): Biociencias

Section

Articles

License

How to Cite

Advances in inmunnology of transplants. (2011). Biociencias, 6(1), 81-88. https://doi.org/10.18041/2390-0512/bioc..1.2765